Your browser doesn't support javascript.
loading
The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent.
Middelburg, Jim; Ghaffari, Soroush; Schoufour, Tom A W; Sluijter, Marjolein; Schaap, Gaby; Göynük, Büsra; Sala, Benedetta M; Al-Tamimi, Lejla; Scheeren, Ferenc; Franken, Kees L M C; Akkermans, Jimmy J L L; Cabukusta, Birol; Joosten, Simone A; Derksen, Ian; Neefjes, Jacques; van der Burg, Sjoerd H; Achour, Adnane; Wijdeven, Ruud H M; Weidanz, Jon; van Hall, Thorbald.
Afiliação
  • Middelburg J; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Ghaffari S; Department of Biology, College of Science, The University of Texas at Arlington, Arlington, TX, USA.
  • Schoufour TAW; Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Sluijter M; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Schaap G; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Göynük B; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Sala BM; Science for Life Laboratory, Department of Medicine, Karolinska Institute & Division of Infectious Diseases, Karolinska University Hospital, 171 65 Solna, Sweden.
  • Al-Tamimi L; Science for Life Laboratory, Department of Medicine, Karolinska Institute & Division of Infectious Diseases, Karolinska University Hospital, 171 65 Solna, Sweden.
  • Scheeren F; Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Franken KLMC; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Akkermans JJLL; Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Cabukusta B; Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Joosten SA; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Derksen I; Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Neefjes J; Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • van der Burg SH; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Achour A; Science for Life Laboratory, Department of Medicine, Karolinska Institute & Division of Infectious Diseases, Karolinska University Hospital, 171 65 Solna, Sweden.
  • Wijdeven RHM; Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Weidanz J; Abexxa Biologics, Inc., Arlington, TX, USA; College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX, USA.
  • van Hall T; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: t.van_hall@lumc.nl.
Cell Rep ; 42(12): 113516, 2023 12 26.
Article em En | MEDLINE | ID: mdl-38048225
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Histocompatibilidade Classe I / Neoplasias Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígenos de Histocompatibilidade Classe I / Neoplasias Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article